Skip to main content

Rabbit Recombinant Monoclonal ARIH2/TRIAD1 antibody. Suitable for WB and reacts with Rat, Human samples.

Be the first to review this product! Submit a review

Images

Western blot - Anti-ARIH2/TRIAD1 antibody [EPR7671] (AB133653), expandable thumbnail
  • OI-RD Scanning - Anti-ARIH2/TRIAD1 antibody [EPR7671] (AB133653), expandable thumbnail

Key facts

Isotype
IgG
Host species
Rabbit
Storage buffer

pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 50% Tissue culture supernatant, 40% Glycerol (glycerin, glycerine), 9% PBS, 0.05% BSA

Form
Liquid
Clonality
Monoclonal

Immunogen

  • The exact immunogen used to generate this antibody is proprietary information.

Reactivity data

Select an application
Product promiseTestedExpectedPredictedNot recommended
WBFlow CytIHC-P
Human
Tested
Not recommended
Not recommended
Mouse
Predicted
Not recommended
Not recommended
Rat
Tested
Not recommended
Not recommended

Tested
Tested

Species
Rat
Dilution info
1/1000 - 1/10000
Notes

-

Species
Human
Dilution info
1/1000 - 1/10000
Notes

-

Predicted
Predicted

Species
Mouse
Dilution info
-
Notes

-

Not recommended
Not recommended

Species
Rat, Human, Mouse
Dilution info
-
Notes

-

Not recommended
Not recommended

Species
Rat, Human, Mouse
Dilution info
-
Notes

-

Associated Products

Select an associated product type

1 product for Alternative Product

Target data

Function

E3 ubiquitin-protein ligase, which catalyzes ubiquitination of target proteins together with ubiquitin-conjugating enzyme E2 UBE2L3 (PubMed:16118314, PubMed:17646546, PubMed:19340006, PubMed:24076655, PubMed:33268465, PubMed:34518685, PubMed:38418882). Acts as an atypical E3 ubiquitin-protein ligase by working together with cullin-5-RING ubiquitin ligase complex (ECS complex, also named CRL5 complex) and initiating ubiquitination of ECS substrates: associates with ECS complex and specifically mediates addition of the first ubiquitin on ECS targets (PubMed:33268465, PubMed:34518685, PubMed:38418882). The initial ubiquitin is then elongated (PubMed:33268465). E3 ubiquitin-protein ligase activity is activated upon binding to neddylated form of the cullin-5 (CUL5) component of the ECS complex (PubMed:24076655). Together with the ECS(ASB9) complex, catalyzes ubiquitination of CKB (PubMed:33268465). Promotes ubiquitination of DCUN1D1 (PubMed:30587576). Mediates 'Lys-6', 'Lys-48'- and 'Lys-63'-linked polyubiquitination (PubMed:16118314, PubMed:17646546, PubMed:19340006). May play a role in myelopoiesis (PubMed:19340006). (Microbial infection) Following infection by HIV-1 virus, acts together with a cullin-5-RING E3 ubiquitin-protein ligase complex (ECS complex) hijacked by the HIV-1 Vif protein, to catalyze ubiquitination and degradation of APOBEC3F and APOBEC3G.

Alternative names

Recommended products

Rabbit Recombinant Monoclonal ARIH2/TRIAD1 antibody. Suitable for WB and reacts with Rat, Human samples.

Key facts

Isotype
IgG
Form
Liquid
Clonality
Monoclonal
Immunogen
  • The exact immunogen used to generate this antibody is proprietary information.
Clone number
EPR7671
Purification technique
Affinity purification Protein A
Dissociation constant
9 x 10-12 M
Concentration
Loading...

Storage

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
-20°C
Storage information
Stable for 12 months at -20°C

Notes

Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

This product is a recombinant monoclonal antibody, which offers several advantages including:

  • - High batch-to-batch consistency and reproducibility
  • - Improved sensitivity and specificity
  • - Long-term security of supply
  • - Animal-free batch production

For more information, read more on recombinant antibodies.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

ARIH2 also known as TRIAD1 is a RING-between-RING (RBR) E3 ubiquitin-protein ligase. It weights approximately 65 kDa. This protein facilitates the transfer of ubiquitin from E2 enzymes to substrates marking them for proteasomal degradation. ARIH2 is located mostly in the cytoplasm and nucleoplasm with high expression in immune cells such as macrophages and dendritic cells. It regulates ubiquitination which is important for controlling protein levels in the cell affecting cellular signal pathways and homeostasis.

Biological function summary

ARIH2 acts as an essential modulator of immune responses. By associating with the LUBAC complex (linear ubiquitin chain assembly complex) this protein contributes to the linear ubiquitination of specific substrates modulating immune signaling. Its activity affects the NF-κB signaling pathway a vital pathway in inflammation and immunity. ARIH2 influences anti-inflammatory responses and may balance immune homeostasis making it a critical player in immune system regulation.

Pathways

ARIH2 plays a significant role in the ubiquitylation pathway and the NF-κB signaling pathway. The protein cooperates with other members of the pathway like HOIP and SHARPIN to mediate immune responses through linear ubiquitin chains. This regulation influences the activation of NF-κB leading to changes in gene expression related to immune and inflammatory responses. ARIH2 is also involved in the regulation of the Wnt signaling pathway where it interacts with various signaling proteins to modulate developmental processes and cellular growth.

Associated diseases and disorders

ARIH2 has implications in autoimmune diseases and cancer. Its regulation of immune responses connects it to autoimmune conditions where the body's immune system attacks its own cells. By influencing NF-κB signaling through proteins like LUBAC ARIH2 affects inflammation contributing to the pathogenesis of autoimmune diseases. In cancer ARIH2's role in protein degradation pathways can alter cell growth and survival connecting it to tumor development and progression. Its interaction with proteins such as HOIP in these pathways suggests its potential as a therapeutic target for both autoimmune disorders and cancer.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

  • Western blot - Anti-ARIH2/TRIAD1 antibody [EPR7671] (ab133653), expandable thumbnail

    Western blot - Anti-ARIH2/TRIAD1 antibody [EPR7671] (ab133653)

    All lanes: Western blot - Anti-ARIH2/TRIAD1 antibody [EPR7671] (ab133653) at 1/1000 dilution

    Lane 1: 293T cell lysate at 10 µg

    Lane 2: Jurkat cell lysate at 10 µg

    Lane 3: HeLa cell lysate at 10 µg

    Lane 4: PC12 cell lysate at 10 µg

    Secondary

    All lanes: Goat anti-Rabbit HRP at 1/2000 dilution

    Predicted band size: 57 kDa

  • OI-RD Scanning - Anti-ARIH2/TRIAD1 antibody [EPR7671] (ab133653), expandable thumbnail

    OI-RD Scanning - Anti-ARIH2/TRIAD1 antibody [EPR7671] (ab133653)

    We have systematically measured KD (the equilibrium dissociation constant between the antibody and its antigen), of more than 840 recombinant antibodies to assess not only their individual KD values but also to see the average affinity of antibody.
    Based on the comparison with published literature values for mouse monoclonal antibodies, Recombinant antibodies appear to be on average 1-2 order of magnitude higher affinity.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com